CRL
Charles River Laboratories International·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Buy"
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CRL
Charles River Laboratories International, Inc.
A leading global provider of solutions that accelerate the early-stage drug discovery and development process
Life Science Tools and Services
--
06/23/2000
New York Stock Exchange
20,100
12-31
Common stock
251 Ballardvale Street, Wilmington, Massachusetts 01887
--
Charles River Laboratories International, Inc., which began operations in 1947, is a Delaware corporation. The company is a leading non-clinical global drug development partner with a mission to create healthier lives. Building on their original core competencies in laboratory animal medicine and science (research model technology), the company has developed a diverse portfolio of discovery and security assessment services, including good laboratory practice (GLP) and non-GLP, to support clients from target identification to non-clinical development. Leveraging their broad portfolio of products and services enables clients to create more efficient and flexible drug development models, thereby reducing their costs, increasing their productivity and effectiveness, and increasing their speed to market.
Earnings Call
Q1/2025
Estimate EPS2.07
Actual EPS2.34
Estimate Revenue941.94M
Actual Revenue984.20M
Contradictions Unveiled: Charles River Laboratories' Q1 2025 Earnings Call Highlights FDA Initiatives, Biotech Demand, and Pricing Pressures
May 07,2025 07:22
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS2.49
Actual EPS3.12
Estimate Revenue985.08M
Actual Revenue1.03B
Charles River Laboratories Q2 2025: Navigating Contradictions in Demand, Pricing, and Margins
Aug 12,2025 04:17
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS2.34
Actual EPS2.43
Estimate Revenue990.79M
Actual Revenue1.00B
Charles River Laboratories' Q3 2025 Earnings Call: Contradictions Emerge on Demand, CDMO Performance, Divestiture Impact, and Pharma Trends
Nov 05,2025 09:10
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CRL has released its 2025 Q3 earnings. EPS was reported at 2.43, versus the expected 2.34, beating expectations. The chart below visualizes how CRL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CRL has released its 2025 Q3 earnings report, with revenue of 1.00B, reflecting a YoY change of -0.49%, and net profit of 55.56M, showing a YoY change of -20.97%. The Sankey diagram below clearly presents CRL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
